Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna reported an open-market sale of 6,625 Class A Ordinary Shares at $46.69 per share on April 9, 2026. After this transaction, he directly holds 27,418 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than timed discretionarily.
Kiniksa Pharmaceuticals International, plc chief operating officer Moat Ross reported an open-market sale of 1,703 Class A Ordinary Shares on April 9, 2026 at $46.69 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan entered on November 13, 2024, and Ross now directly holds 12,029 shares.
Kiniksa Pharmaceuticals, Ltd. Form 144 notice lists proposed sales of Class A ordinary shares tied to equity compensation and a restricted stock lapse. The excerpt shows a 04/07/2026 restricted-stock lapse and a proposed sale quantity listed as 79,513.00, plus a recent reported sale of 114,989.00 shares on 04/06/2026.
Kiniksa Pharmaceuticals International, plc filed a Form 144 reporting proposed dispositions of Class A ordinary shares. The filing lists a total of 6,625 shares tied to restricted stock lapses on 04/01/2026 (4,359 shares) and 04/07/2026 (2,266 shares).
Kiniksa Pharmaceuticals International, plc chief strategy officer Eben Tessari exercised Restricted Share Units into common shares and had shares withheld for taxes. On April 7, 2026, 2,726 RSUs were converted into 2,726 Class A Ordinary Shares. Of these, 846 shares at $48.94 per share were withheld to satisfy tax obligations, leaving Tessari with 23,130 Class A Ordinary Shares held directly. Each RSU represents a right to receive one Class A Ordinary Share and the RSU grant vests in four equal annual installments starting on April 7, 2023, over a four-year period.
Kiniksa Pharmaceuticals International, plc chief financial officer Mark Ragosa exercised 2,694 Restricted Share Units into Class A Ordinary Shares on April 7, 2026. Each RSU converts into one share and is part of a grant that vests in four equal annual installments starting April 7, 2022.
To cover tax obligations from this vesting, 1,303 Class A Ordinary Shares were withheld at a price of $48.94 per share, rather than sold in the open market. After these compensation-related transactions, Ragosa directly holds 16,154 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc Chairman & CEO Sanj K. Patel reported multiple equity transactions in the company’s Class A Ordinary Shares. On April 6, 2026, he exercised options for 7,278 shares at $10.36 per share and sold 7,278 shares at a weighted average price of about $50.01 in an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan.
On April 7, 2026, 9,991 Restricted Share Units converted into the same number of Class A Ordinary Shares, credited to The Patel Family Irrevocable Trust of 2025. Of these, 4,831 shares were withheld at $48.94 per share to cover tax obligations, leaving 76,174 shares in that trust. Additional indirect holdings include 109,795 shares in The Marina 2016 Irrevocable Trust and 51,794 shares in The Anglia 2013 Revocable Trust.
Kiniksa Pharmaceuticals’ chief medical officer John F. Paolini exercised 2,497 Restricted Share Units into Class A Ordinary Shares on April 7, 2026. Of these shares, 1,208 were withheld at $48.94 per share to cover tax obligations, and he now directly holds 65,623 Class A Ordinary Shares. The RSUs come from a grant that vests over four years, with 25% vesting on each anniversary of the April 7, 2022 grant date.
Kiniksa Pharmaceuticals International, plc chief operating officer Ross Moat reported a series of equity transactions involving Class A Ordinary Shares. On April 7, 2026, he exercised 2,477 Restricted Share Units, receiving an equal number of Class A Ordinary Shares as the RSUs converted one-for-one.
On the same date, 774 shares were disposed of at $48.94 per share to cover tax obligations related to the equity award, a non-market tax-withholding transaction. On April 6, 2026, he completed an open‑market sale of 2,367 Class A Ordinary Shares at $48.58 per share under a pre‑arranged Rule 10b5‑1 trading plan. Following these transactions, he directly holds 12,029 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna exercised restricted share units and had shares withheld for taxes. On this date, 3,932 Restricted Share Units converted into 3,932 Class A Ordinary Shares. Of these, 1,666 shares were disposed of to cover tax obligations at a price of $48.94 per share, a non-market tax-withholding transaction. After these compensation-related events, Megna directly held 34,043 Class A Ordinary Shares. The RSUs vest over four years, with 25% vesting on each yearly anniversary of the April 7, 2022 grant date.